NBIX

Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top value stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company features an attractive forward P/E ratio of 14.86, a Value Style Score of B, and has seen upward earnings estimate revisions with a consensus estimate of $9.09 per share for fiscal 2026, along with an average earnings surprise of +13.6%.

A comparison of two Medical-Drugs sector stocks reveals that Neurocrine Biosciences (NBIX) presents a better value opportunity than Sandoz Group AG (SDZNY). Both stocks hold a Zacks Rank #2 (Buy) with positive earnings outlooks, but NBIX's superior valuation metrics—including a lower forward P/E ratio of 15.55 versus SDZNY's 20.49, and a PEG ratio of 0.53 compared to 1.69—earned it a Value grade of B versus SDZNY's C grade.

Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top growth stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasting year-over-year earnings growth of 42.3% for fiscal 2026, with a consensus earnings estimate of $9.09 per share and an average earnings surprise of +13.6%.

Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.